Core Insights - The report maintains a positive outlook on the agricultural sector, particularly in the pig farming industry, with a focus on the potential for value reassessment of pig farming companies [2][5] - The agricultural sector has shown a mixed performance recently, with the overall index up by 2.02% week-on-week, while the pig farming segment has seen a notable increase of 4.39% [11][12] Livestock Farming Data Tracking - Pig prices have slightly declined this week due to sufficient supply and market sentiment being buoyed by government stockpiling efforts [7][16] - The number of breeding sows has shown a slight decrease, with July figures indicating a 0.02% month-on-month decline [20][22] - The average price for market pigs as of August 28 is 13.70 CNY/kg, reflecting a week-on-week decrease of 1.51% [30][36] - Profitability in pig farming remains positive for self-bred pigs, with a profit of 32.24 CNY per head, while purchased piglets show a loss of 148.41 CNY per head [38][41] Poultry Farming Data Tracking - The price of white feathered chickens remains stable, with an average price of 7.33 CNY/kg as of August 29 [39][42] - The ongoing avian influenza outbreaks in Europe and the U.S. create uncertainty in the supply of breeding chickens, which may benefit the white feathered chicken industry [39][40] Animal Health Data Tracking - The demand for animal health products is expected to rebound, driven by the recovery in livestock numbers and the introduction of new products [47] - Significant growth in the issuance of veterinary vaccine approvals has been noted, particularly for African swine fever vaccines, which may enhance market interest [47][51] Seed Industry Data Tracking - The average prices for wheat, soybean meal, and corn have decreased slightly, with wheat at 2429 CNY/ton, soybean meal at 3071 CNY/ton, and corn at 2365 CNY/ton as of August 29 [52][53] - The USDA's August report indicates a decrease in global corn stocks for the 2025/26 season compared to the previous year, while soybean stocks are also projected to decline [54][56] Pet Industry Data Tracking - Pet food exports have seen a decline, with July figures showing a 3.0% year-on-year decrease, amounting to 930 million CNY [58][60] - Domestic sales in the pet food market continue to grow, with notable increases in sales for brands like Guai Bao and Pei Di [60][61] - The recent Asia Pet Expo showcased over 2600 exhibitors and more than 20000 brands, indicating a robust growth in the pet industry [61][62]

Investment Rating - The industry is rated as "Buy" [4] Core Insights - In July, the Ministry of Agriculture and Rural Affairs reported a stable yet slightly declining breeding sow inventory at 40.42 million heads, with a significant increase in pig slaughtering volume, reaching 31.66 million heads, a month-on-month increase of 5.3% and a year-on-year increase of 30.4% [1][3] - The average price of commodity pigs showed a slight rebound to 14.84 yuan/kg in July, with a month-on-month increase of 1.9% but a year-on-year decrease of 21.6% [1] - The overall profitability of the industry remained marginal, with average profits per head for large-scale farms at 21 yuan and for smallholders at 6 yuan [1] Summary by Sections 1. Industry Performance - The agricultural sector outperformed the market, with the agricultural index rising by 2.02% compared to the Shanghai Composite Index's 0.84% increase [13] - The livestock farming sector saw a rise of 4.39%, while other sectors like animal health and fisheries experienced declines [13] 2. Key Data Tracking - The average price of live pigs was reported at 13.66 yuan/kg, down 0.65% week-on-week, while the average price of piglets was 27.14 yuan/kg, down 2.3% [22] - The average slaughter weight of pigs decreased to 127.83 kg, with a slight decline of 0.15 kg week-on-week [22] 3. Investment Recommendations - The pig farming sector is expected to enter a long-term profit upcycle, with recommendations for companies such as Muyuan Foods, Wens Foodstuff Group, and Juxing Agriculture [3][68] - The feed and animal health sectors are also highlighted for potential growth, particularly with the recent clinical trials of vaccines [3][68] - The planting chain is recommended for investment due to the upward trend in grain prices, with companies like Suqian Agricultural Development and Beidahuang being noted [3][68] - The pet food sector is experiencing growth, with recommendations for companies like Guibao Pet and Zhongchong Co., Ltd. [3][70]

Core Insights - The company reported a revenue of 1.708 billion yuan for the first half of 2025, representing a year-on-year growth of 20.53%, and a net profit attributable to shareholders of 257 million yuan, up 57.59% year-on-year [1] - The strong performance is attributed to the synergistic growth across various business segments, particularly in the economic animal health sector, which saw significant revenue increases [1][2] Economic Animal Health Segment - The economic animal health segment showed robust growth, with revenue from poultry biological products reaching 611 million yuan, a year-on-year increase of 24.71%, and livestock biological products revenue soaring by 110.55% to 136 million yuan, driven by the integration of foot-and-mouth disease vaccine business and market expansion [2] - The company has deepened strategic partnerships with leading breeding groups, enhancing cost efficiency through a comprehensive service model [2] - The company achieved a significant milestone by obtaining the world's first clinical approval for an mRNA vaccine for food animals, showcasing its leadership in cutting-edge technology [2] Pet Segment Development - The company is committed to building a leading domestic brand in the pet sector, focusing on a "product + supply chain + medical" strategy to drive growth [3] - Revenue from the pet supply chain and products reached 415 million yuan, reflecting a year-on-year growth of 17.94%, with a significant increase in the shipment volume of self-developed products [3] - The company plans to launch new products, including cat interferon and probiotics, to enhance its comprehensive product matrix for prevention, treatment, and nutritional health [3] Profit Forecast and Investment Recommendation - The company projects earnings per share (EPS) of 0.91, 1.08, and 1.16 yuan for 2025 to 2027, corresponding to dynamic price-to-earnings ratios of 25, 21, and 20 times, respectively, maintaining a "buy" rating [3]

Group 1 - The report highlights a sustained strengthening of GMV inflection points, indicating optimism for long-term growth in the education sector, particularly for Oriental Selection [4][5] - The report notes a significant increase in the dividend payout ratio to 60% for Excellence Education Group, which may support revenue growth in the second half of 2025 [10][11] - Shanghai Film's performance is under short-term pressure, but the release of "Wang Wang Mountain Little Monster" is expected to provide performance elasticity [13][15] Group 2 - Huabei Mining's revenue for H1 2025 decreased by 45% year-on-year, but cost control measures are expected to enhance future performance as quality projects are gradually put into production [19][21] - The report indicates that the pet ecosystem construction by Reap Bio is becoming increasingly comprehensive, with a notable increase in revenue and net profit in H1 2025 [24][25] - Silver Wheel's revenue and net profit showed significant growth in Q2 2025, driven by dual engines of "server liquid cooling + robotic joints" [27][29] Group 3 - Shaanxi Coal's production and sales volumes remained stable, with a slight increase in coal production in H1 2025, despite a decrease in revenue [31][33] - China Ruyi's net profit turned from loss to profit in H1 2025, driven by game publishing and content investment [36][37] - Light Media's animation production capacity continues to improve, with IP operations expected to become a new growth point [40][42] Group 4 - Cambrian's revenue for H1 2025 saw an extraordinary increase of 4347.82% year-on-year, with net profit also experiencing substantial growth [46]

Market Overview - The animal health sector experienced a decline of 1.01% on August 28, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Stock Performance - Notable gainers included: - Qudongli (838275) with a closing price of 11.07, up 5.23% [1] - Xianfeng Holdings (002141) at 4.19, up 1.21% [1] - Zhongmu Co. (600195) at 7.63, up 0.66% [1] - Major decliners included: - *ST Lvkang (002868) at 27.20, down 3.51% [2] - Shenyuan Bio (688098) at 12.59, down 2.70% [2] - KQ Bio (688526) at 18.40, down 1.55% [2] Capital Flow - The animal health sector saw a net outflow of 136 million yuan from institutional investors, while retail investors contributed a net inflow of 101 million yuan [2] - The detailed capital flow for key stocks showed: - Zhongmu Co. had a net outflow of 18.59 million yuan from institutional investors [3] - *ST Lvkang experienced a significant net outflow of 7.31 million yuan from institutional investors [3] - Retail investors showed a net inflow of 5.64 million yuan into *ST Lvkang [3]

Core Insights - The pet economy is experiencing significant growth, prompting many listed companies to enter the pet sector, reflecting a strategic intent to seek new growth avenues and the maturation of China's pet consumption market [1][7] Group 1: Company Movements - Jinhe Biological (002688.SZ) announced the establishment of a wholly-owned subsidiary, Jinhe Aichongyi (Shanghai) Biotechnology Co., with a registered capital of 10 million yuan, focusing on AI-enabled pet care solutions [1][3] - Delisi (002330.SZ) signed a strategic cooperation agreement with Xiamen Haifusheng Food Group and New Sanhe (Yantai) Food Co., to collaborate on product supply, market expansion, and the development of freeze-dried pet food [4][5] - Huashanghuan (002695.SZ) acquired a 51% stake in Fujian Lixing Food Co. for 494.7 million yuan, which has significant freeze-drying production capabilities [6] Group 2: Market Trends - The global pet industry is projected to grow from approximately $207 billion in 2024 to $270.8 billion by 2029, with a compound annual growth rate (CAGR) of 5.5% [7] - The Chinese pet market is expected to reach 300.2 billion yuan in 2024, reflecting a 7.5% increase from 2023, and is projected to grow to 404.2 billion yuan by 2027 [7] Group 3: Company Performance - Companies in the pet industry are showing strong performance, with Guibao Pet (301498.SZ) reporting a 32.72% increase in revenue to 3.221 billion yuan in the first half of 2025 [8] - Zhongchong Co. (002891.SZ) achieved a revenue of 2.432 billion yuan, a 24.32% year-on-year increase, with a net profit growth of 42.56% [8] - Tianyuan Pet (301335.SZ) reported a revenue of 1.435 billion yuan, up 14.59%, and a net profit increase of 20.14% [8] Group 4: Industry Insights - Analysts indicate that the pet sector will maintain high growth, with trends towards functional and refined products tailored to different pet life stages [9] - Companies are encouraged to innovate and differentiate to build core competitiveness amid increasing industry competition [9]

2025 年 08 月 28 日 公司研究 评级：买入(维持) 研究所： 证券分析师： 程一胜 S0350521070001 chengys01@ghzq.com.cn 证券分析师： 熊子兴 S0350522100002 xiongzx@ghzq.com.cn [Table_Title] 主业持续向好，宠物生态圈建设日益完善 ——瑞普生物（300119）2025 年中报点评 最近一年走势 | 相对沪深 300 | 表现 | | 2025/08/27 | | --- | --- | --- | --- | | 表现 | 1M | 3M | 12M | | 瑞普生物 | 2.6% | -13.2% | 88.6% | | 沪深 300 | 6.3% | 14.2% | 32.7% | | 市场数据 | | | 2025/08/27 | | 当前价格（元） | | | 22.48 | | 52 周价格区间（元） | | | 11.25-28.90 | | 总市值（百万） | | | 10,447.69 | | 流通市值（百万） | | | 7,529.95 | | 总股本（万股） | | | 46,475.47 | ...

Industry Overview - The pet medical market is transitioning from a niche sector to a competitive arena, driven by the increasing demand for pet healthcare as pets are considered family members [1][2] - The pet medical market is projected to account for approximately 28% of total pet consumption in urban China by 2024, with a market size of around 800 billion yuan [2] Company Involvement - Numerous listed companies and large pharmaceutical firms are entering the pet medicine sector, including Hai Zheng Pharmaceutical, Huadong Medicine, and Reap Bio [2][3] - Hai Zheng Dongbao, a subsidiary of Hai Zheng Pharmaceutical, has become a leading brand in the domestic pet medicine market, focusing on deworming drugs and vaccines [3] Market Potential - The pet medicine market is primarily composed of deworming drugs, skin disease medications, and vaccines, with deworming drugs accounting for about 60% of the market share [4] - There is a significant demand for medications targeting elderly pets, chronic diseases, and tumors, indicating a potential growth area for the pet medicine industry [5][6] R&D and Innovation - The R&D costs for pet medicines are significantly lower than for human medicines, with pet innovation drugs typically costing between 20 million to 30 million yuan [2][5] - Hai Zheng Dongbao plans to leverage its human medicine resources to enhance its pet medicine R&D capabilities, aiming to reduce costs and risks [3][6] Vaccine Development - The domestic pet vaccine market is experiencing accelerated progress in local alternatives, with the first domestically approved cat trivalent vaccine set to launch in January 2024 [7] - By mid-2025, 11 domestic cat trivalent vaccines are expected to be available, with domestic vaccines capturing a 25% market share [7][8] Future Outlook - The aging pet population is anticipated to drive the demand for pet healthcare services, with over 30 million pets expected to enter middle age in the next three years [5] - Companies are focusing on developing a product matrix that includes both vaccines and chemical drugs to meet the growing market needs [8]

上 市 公 司 农林牧渔 ——25H1 业绩高增，畜禽动保主业业绩向好，宠物板块奠定长期增长 报告原因：有业绩公布需要点评 增持（维持） | 市场数据： 2025 年 08 月 27 日 | | | --- | --- | | 收盘价（元） | 22.48 | | 一年内最高/最低（元） | 28.90/11.25 | | 市净率 | 2.3 | | 股息率%（分红/股价） | 1.33 | | 流通 A 股市值（百万元） | 7,530 | | 上证指数/深证成指 3,800.35/12,295.07 | | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 06 月 30 日 | | --- | --- | | 每股净资产（元） | 9.82 | | 资产负债率% | 36.00 | | 总股本/流通 A 股（百万） | 465/335 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 08-27 09-27 10-27 11-27 12-27 01-27 02-27 03-27 04-27 05-27 06-27 07-27 08-27 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's revenue for H1 2025 reached 1.708 billion yuan, a year-on-year increase of 20.53%, with a net profit attributable to the parent company of 257 million yuan, up 57.59% year-on-year [4][5] - The poultry vaccine segment showed significant growth, with a focus on new product launches in the second half of the year [5] - The pet medical segment is expected to open up long-term growth opportunities, supported by a robust supply chain and product offerings [6] Financial Performance - In H1 2025, the company achieved a gross margin of 28.44%, an increase of 2.36 percentage points year-on-year, driven by product mix optimization [4] - The company plans to achieve revenues of 3.723 billion yuan, 4.334 billion yuan, and 4.939 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 500 million yuan, 605 million yuan, and 702 million yuan [7] Segment Analysis - The poultry vaccine segment generated 611 million yuan in revenue, a year-on-year increase of 24.71%, while the livestock biological products segment saw a remarkable growth of 110.55% [5] - The pet medical segment's revenue reached 415 million yuan, growing by 17.94% year-on-year, with plans to launch new products to enhance the product matrix [6]